Interestingly, a recent clinical trial (TAILORx, Trial Assigning Individualized Options for Treatment) evaluated on early-stage HR-positive/HER2-negative breast cancer patients, the impact of endocrine therapy as compared to chemoendocrine therapy [513]. This evidence concerns the gene ERBB2 and breast cancer.